Form 4 for BDX Becton Dickinson
Accepted 2026-01-16 00:00:00 ET · period of report 2026-01-15 · accession 0001944816-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | S - Sale+OE | $207.46 | -1,610 | 13.1K | -11% | -$334.0K |
| D | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | M - OptEx | $167.91 | +3,054 | 16.2K | +23% | +$512.8K |
| D | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | D - Sale to Iss | $209.00 | -2,454 | 13.7K | -15% | -$512.9K |
| D | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | M - OptEx | $0.00 | -3,054 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-15 | S | D | 1,010 | $206.54 | 12,095 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-15 | S | D | 600 | $209.00 | 13,105 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-15 | M | A | 3,054 | $167.91 | 16,159 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-15 | D | D | 2,454 | $209.00 | 13,705 | D | — | — | |
| 5 | Derivative | Stock Appreciation Rights | 2026-01-15 | M | D | 3,054 | $0.00 | 0 | D | $167.91 · 2017-11-26 to 2026-11-26 | 3,054 Common Stock | (F1) The stock appreciation rights vested in four annual installments beginning one year from the grant date. |